OpGen, Inc.
US ˙ OTCPK

Introduction

This page provides a comprehensive analysis of the known insider trading history of Timothy C Dec. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Timothy C Dec has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SUPN / Supernus Pharmaceuticals, Inc. Senior Vice-President & CFO 1,246
US:OPGN / OpGen, Inc. Chief Financial Officer 584
US:TSSI / TSS, Inc. Chief Financial Officer 150,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Timothy C Dec. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases OPGN / OpGen, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in OPGN / OpGen, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-07-18 OPGN DEC TIMOTHY C 65,000 0.4000 3,467 7.5000 26,000 2 38000 131,682,000 506,469.23
2016-05-19 OPGN DEC TIMOTHY C 43,716 2,332
2015-05-08 OPGN,OPGNW DEC TIMOTHY C 4,000 6.0000 213 112.5000 24,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OPGN / OpGen, Inc. Insider Trades
Insider Sales OPGN / OpGen, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in OPGN / OpGen, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OPGN / OpGen, Inc. Insider Trades
Insider Purchases SUPN / Supernus Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in OPGN / OpGen, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SUPN / Supernus Pharmaceuticals, Inc. Insider Trades
Insider Sales SUPN / Supernus Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in OPGN / OpGen, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-08-22 SUPN DEC TIMOTHY C 11,780 44.4900 11,780 44.4900 524,092 4 44.3200 -2,002 -0.38

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SUPN / Supernus Pharmaceuticals, Inc. Insider Trades
Insider Purchases TSSI / TSS, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in OPGN / OpGen, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TSSI / TSS, Inc. Insider Trades
Insider Sales TSSI / TSS, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in OPGN / OpGen, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TSSI / TSS, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Timothy C Dec as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-26 2025-08-22 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
S - Sale -11,780 1,246 -90.43 44.49 -524,092 55,435
2025-03-11 2025-03-10 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -955 12,681 -7.00 32.06 -30,617 406,553
2025-03-11 2025-03-10 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
M - Exercise 1,800 13,636 15.21
2025-03-11 2025-03-10 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -1,062 11,836 -8.23 32.06 -34,048 379,462
2025-03-11 2025-03-10 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
M - Exercise 2,000 12,898 18.35
2025-03-05 2025-03-05 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -1,330 10,898 -10.88 33.05 -43,956 360,179
2025-03-05 2025-03-05 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -1,587 12,228 -11.49 33.05 -52,450 404,135
2025-03-05 2025-03-05 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -276 13,815 -1.96 33.05 -9,122 456,586
2025-02-24 2025-02-23 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
A - Award 2,500 14,091 21.57
2025-02-24 2025-02-22 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
A - Award 3,000 11,591 34.92
2025-02-24 2025-02-22 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
A - Award 500 8,591 6.18
2024-02-27 2024-02-23 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -1,314 7,190 -15.45 29.06 -38,185 208,941
2024-02-27 2024-02-23 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
A - Award 2,500 8,504 41.64
2024-02-26 2024-02-22 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
A - Award 500 6,004 9.08
2023-10-13 2023-10-13 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -1,911 5,089 -27.30 26.91 -51,425 136,945
2023-10-13 2023-10-13 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
M - Exercise 4,000 7,000 133.33
2023-05-12 2023-05-11 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -709 2,650 -21.11 36.47 -25,857 96,646
2023-05-12 2023-05-11 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
M - Exercise 1,500 3,359 80.69
2023-04-12 2023-02-22 4/A SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -193 1,148 -14.39 38.57 -7,444 44,278
2023-04-12 2023-02-22 4/A SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
A - Award 500 1,341 59.45
2023-04-10 2023-03-14 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
F - Taxes -789 2,052 -27.77 38.65 -30,495 79,310
2023-04-10 2023-03-14 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
M - Exercise 1,500 2,841 111.86
2023-02-24 2023-02-22 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Common Stock
A - Award 500 1,341 59.45
2022-02-25 2022-02-22 4/A SUPN SUPERNUS PHARMACEUTICALS, INC.
Restricted Stock Units
A - Award 2,000 2,000
2022-02-25 2022-02-22 4/A SUPN SUPERNUS PHARMACEUTICALS, INC.
Employee Stock Option (Right to Buy)
A - Award 25,000 25,000
2022-02-24 2022-02-22 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Restricted Stock Units
A - Award 2,000 2,000
2022-02-24 2022-02-22 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Employee Stock Option (Right to Buy)
A - Award 25,000 25,000
2021-08-24 2021-08-23 4 SUPN SUPERNUS PHARMACEUTICALS, INC.
Employee Stock Option (Right to Buy)
A - Award 85,000 85,000
2021-05-19 2021-05-17 4 OPGN OPGEN INC
Restricted Stock Units
M - Exercise -583 584 -49.96
2021-05-19 2021-05-17 4 OPGN OPGEN INC
Common Stock
M - Exercise 583 1,509 62.96
2021-03-05 2021-03-03 4 OPGN OPGEN INC
Stock Option Award
A - Award 42,500 42,500
2021-03-05 2021-03-03 4 OPGN OPGEN INC
Restricted Stock Award
A - Award 42,500 42,500
2020-10-02 2020-09-30 4 OPGN OPGEN INC
Stock Option Award
A - Award 210,000 210,000
2020-05-19 2020-05-17 4 OPGN OPGEN INC
Restricted Stock Unit
M - Exercise -583 1,167 -33.31
2020-05-19 2020-05-17 4 OPGN OPGEN INC
Common Stock
M - Exercise 583 926 169.97
2019-11-12 2019-11-10 4 OPGN OPGEN INC
Restricted Stock Option
M - Exercise -12
2019-11-12 2019-11-10 4 OPGN OPGEN INC
Common Stock
M - Exercise 12 345 3.60
2019-05-20 2019-05-17 4 OPGN OPGEN INC
Restricted Stock Units
A - Award 35,000 35,000
2018-02-27 2018-02-23 4 OPGN OPGEN INC
Restricted Stock Units
M - Exercise -1,400 0 -100.00
2018-02-27 2018-02-23 4 OPGN OPGEN INC
Common Stock
M - Exercise 1,400 6,408 27.96
2018-01-25 2018-01-23 4 OPGN OPGEN INC
Stock Option Award
A - Award -12,000 12,000 -50.00
2017-11-14 2017-11-10 4 OPGN OPGEN INC
Restricted Stock Units
M - Exercise -6,250 12,500 -33.33
2017-11-14 2017-11-10 4 OPGN OPGEN INC
Common Stock
M - Exercise 6,250 125,216 5.25
2017-08-11 2017-08-09 4 OPGN OPGEN INC
Restricted Stock Units
A - Award 35,000 35,000
2017-08-11 2017-08-09 4 OPGN OPGEN INC
Stock Option Award
A - Award 60,000 60,000
2017-07-18 2017-07-18 4 OPGN OPGEN INC
Warrants to purchase Common Stock
A - Award 65,000 65,000
2017-07-18 2017-07-18 4 OPGN OPGEN INC
Common Stock
P - Purchase 65,000 118,966 120.45 0.40 26,000 47,586
2017-02-27 2017-02-23 4 OPGN OPGEN INC
Stock Option Award
A - Award 68,000 68,000
2017-02-10 2016-11-10 5 OPGN OPGEN INC
Restricted Stock Units
M - Exercise -6,250 18,750 -25.00
2017-02-10 2016-11-10 5 OPGN OPGEN INC
Common Stock
M - Exercise 6,250 53,966 13.10
2016-06-14 2016-06-13 4 OPGN OPGEN INC
Stock Option Award
A - Award 60,000 60,000
2016-05-23 2016-05-19 4 OPGN OPGEN INC
Warrants
P - Purchase 43,716 43,716
2016-05-23 2016-05-19 4 OPGN OPGEN INC
Common Stock
P - Purchase 43,716 47,716 1,092.90
2015-11-12 2015-11-10 4 OPGN OPGEN INC
Restricted Stock Units
A - Award 25,000 25,000
2015-11-12 2015-11-10 4 OPGN OPGEN INC
Stock Options (right to buy)
A - Award 50,000 50,000
2015-05-12 2015-05-08 4 OPGN,OPGNW OPGEN INC
Warrants
P - Purchase 4,000 4,000
2015-05-12 2015-05-08 4 OPGN,OPGNW OPGEN INC
Common Stock
P - Purchase 4,000 4,000 6.00 24,000 24,000
2015-05-06 2015-05-04 4 OPGN,OPGNW OPGEN INC
Stock Option (right to buy)
A - Award 114,320 114,320
2012-06-08 2012-06-06 4 FIGI.PK Fortress International Group, Inc.
Employee Stock Option (Right to Buy)
A - Award 150,000 150,000
2012-01-04 2012-01-03 4 FIGI Fortress International Group, Inc.
Common Stock
F - Taxes -8,180 285,005 -2.79 0.88 -7,198 250,804
2008-03-20 3 FIGI Fortress International Group, Inc.
Common Stock
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)